Market Herald logo


Be the first with the news that moves the market
  • Pharmaceutical company Starpharma has launched its VivaGel product in the U.K. 
  • Viva Gel is the company’s flagship product and its latest foray into the women’s health treatment industry
  • The product is being sold through pharmacy giant Mundipharma 
  • Starpharma’s share price is down nearly one per cent today, currently sitting at $1.42 cents per share

Starpharma has launched its flagship VivaGel product in the U.K.

The product is being sold through pharmacy giant Mundipharma, who is also launching VivaGel across Europe. Launches are also planned for Asia in the near future, dependent on regulatory approvals.

“Starpharma and Mundipharma are working closely together to bring this breakthrough product to European women suffering from BV,” Starpharma’s CEO Dr Jackie Fairley said.

The VivaGel products are non-antibiotic treatments for bacterial vaginosis. The product comes in gel form and as a condom.

Bacterial vaginosis is a common condition affecting women, caused by a build up various bacteria on the vagina. Globally, one in three women suffer from the condition.

Published in the International Journal of Microbiology, bacterial vaginosis is classified as a “global concern” based on its risk of spreading sexually transmitted diseases.

Starpharma and Mundipharma said the two companies are continuing to work on gaining regulatory approvals world-wide and continuing the roll out of its products.

Heading into the last hour of today’s trade, Starpharma’s share price is down 2.26 per cent, currently sitting at $1.30 per share.

SPL by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.